Q-omics provides the consensus-scored MYL6P2 profile across patient tissues and cancer cell-line models. MYL6P2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, MYL6P2 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, MYL6P2 RNA expression shows 8,960 significant protein co-abundance associations, with the highest sampling consensus in OV. Together, these results highlight COAD, HNSC, and OV as cancer lineages where MYL6P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYL6P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYL6P2 survival associations across molecular data types. MYL6P2 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYL6P2 RNA expression–survival associations across cancer types. High MYL6P2 expression shows unfavorable associations in ACC and CHOL, but favorable associations in COAD, UCS, OV and KIRP. The COAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify COAD as the clearest survival context for MYL6P2 RNA expression.
This table summarizes MYL6P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MYL6P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYL6P2 shows lower tumor expression in THCA and STAD and higher tumor expression in HNSC, COAD and LIHC. The HNSC box plot shows higher MYL6P2 RNA expression in tumor versus normal tissue (log2 FC = +0.156, t-test p = .004).
This table shows molecular features associated with MYL6P2 in patient tissues and cancer cell lines. In patient samples, MYL6P2 shows the broadest associations at the RNA and protein expression levels, with OV recurring as the lineage with the largest associated feature set.
